Antigen presentation by endothelium: Heparin reduces the immunogenicity of interferon-γ-treated endothelial cells

Transplant Immunology

Volumn 5, Issue 3, 1997, Pages 233-235

  Douglas, Michael S ^a   Rix, David A ^a   Kirby, John A ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPARIN;

ANTIGEN PRESENTATION; CONFERENCE PAPER; ENDOTHELIUM; IMMUNOGENICITY; PRIORITY JOURNAL;

EID: 0030715636     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-3274(97)80043-3     Document Type: Conference Paper

References (19)

1. Pober JS, Orosz CG, Rose ML. Savage COS. Can graft endothelial cells initiate a host anti-graft immune response? Transplantation. 61:1996;343-349.
2. Rix DA, Douglas MS, Talbot D, Dark JH, Kirby JA. Role of glycosaminoglycans in regulation of the immunogenicity of human vascular entothelial cells. Clin Exp. Immunol. 104:1996;60-65.
3. Edgell CJS, McDonald CC, Graham JB. Permanent cell line expressing human factor VIII-related antigen established by hybridization. Proc Natl Acad Sci USA. 80:1983;3734-3737.
4. Edgell C-JS, Haizlip JE, Bagnell CR, et al. Endothelium specific Weibel-Palade bodies in a continuous human cell line EA.hy926. In Vitro Cell Dev Biol. 26:1990;1167-1172.
5. Thornton SC, Mueller SN, Levine EM. Human endothelial cells: use of heparin in cloning and long-term serial cultivation. Science. 222:1983;623-625.
6. Nunez G, Ball EJ, Stastny P. Accessory cell function of human endothelial cells. 1. A subpopulation of Ia positive cells is required for antigen presentation. J Immunol. 131:1983;666-673.
7. Brown KA, Vora A, Biggerstaff J, et al. Application of an immortalized human endothelial cell line to the leukocyte:endothelial adherence assay. J Immunol Methods. 163:1993;13-22.
8. + T cells to endothelial cells in the absence of contaminating accessory cells. Transplantation. 57:1994;1628-1637.
9. Wilson JL, Cunningham AC, Kirby JA. Alloantigen presentation by B cells: analysis of the requirement for B cell activation. Immunology. 86:1995;325-330.
10. Douglas MS, Rix DA, Dark JH, Talbot D, Kirby JA. Examination of the mechanism by which heparin antagonizes activation of a model endothelium by interferon-gamma (IFN-γ). Clin Exp Immunol. 107:1997;578-584.
11. Korlipara LVP, Pleass HCC, Taylor RMR, Forsythe JLR, Proud G, Kirby JA. Cultured endothelium: heparin antagonises the induction of class II molecules by interferon-γ. Transplantation. 58:1994;1426-1429.
12. Daubener W, Nockemann S, Gutsche M, Hadding U. Heparin inhibits the antiparasitic and immune modulatory effects of human recombinant interferon-γ Eur J Immunol. 25:1995;688-692.
13. + T cells. Hepatology. 24:1996;561-567.
14. Page C, Thompson C, Yacoub M, Rose M. Human endothelial stimulation of allogeneic T cells via a CTLA-4 indepedent pathway. Transplant Immunol. 2:1994;342-347.
15. Lider O, Baharav E, Mekori YA, et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest. 83:1989;752-756.
16. Lagodzinski Z., Gorski A., Wasim M. Immunosuppressive action of low-dose heparin: effect on skin allograft survival. Transplantation. 50:1990;714-715.
17. Aziz S, Tada Y, Gordon D, McDonald TO, Fareed J, Verrier ED. A reduction in accelerated graft coronary disease and an improvement in cardiac allograft using low molecular weight heparin in combination with cyclosporine. J Heart Lung Transplant. 12:1993;634-643.
18. Fuller L, Carreno M, Esquenazi V, et al. Characterization of anticanine cytokine monoclonal antibodies specific for IFN-γ-effect of anti-IFN-γ on renal transplant rejection. Tissue Antigens. 43:1994;163-169.
19. Halloran PF, Goes N, Urmson J, et al. MHC expression in organ transplants: lessons from the knock-out mice. Transplant Proc. 29:1997;1041-1044.